LOG IN
SIGN UP
News
CDNA
--
0.00%
--
CareDx to Participate at the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
GlobeNewswire · 20h ago
CareDx (CDNA) Investor Presentation - Slideshow
Seeking Alpha - Article · 5d ago
CareDx to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire · 05/28 12:00
CareDx Presents the Latest AlloSure Data in Virtual Meetings
SOUTH SAN FRANCISCO, Calif., May 27, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
GlobeNewswire · 05/27 11:00
Edited Transcript of CDNA earnings conference call or presentation 30-Apr-20 8:30pm GMT
Q1 2020 CareDx Inc Earnings Call
Thomson Reuters StreetEvents · 05/20 19:59
CareDx Reports Its AlloSeq Tx 17 Wins CE Mark Approval
Benzinga · 05/15 11:10
CareDx's AlloSeq Tx 17 Awarded CE Mark Approval
SOUTH SAN FRANCISCO, Calif., May 15, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
GlobeNewswire · 05/15 11:00
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
Business Wire · 05/14 12:15
CareDx Brings the Transplant Patient Community Together
SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
GlobeNewswire · 05/07 11:00
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap
GlobeNewswire · 05/05 12:00
Here's Why We're Not At All Concerned With CareDx's (NASDAQ:CDNA) Cash Burn Situation
Simply Wall St. · 05/02 13:35
HC Wainwright & Co. Reiterates Buy on CareDx, Lowers Price Target to $40
HC Wainwright & Co. reiterates CareDx (NASDAQ:CDNA) with a Buy and lowers the price target from $43 to $40.
Benzinga · 05/01 11:28
CareDx, Inc (CDNA) CEO Peter Maag on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/01 02:55
CareDx EPS misses by $0.03, beats on revenue
CareDx (NASDAQ:CDNA): Q1 Non-GAAP EPS of $0.00 misses by $0.03; GAAP EPS of -$0.14 misses by $0.01. Revenue of $38.38M (+47.7% Y/Y) beats by $0.11M. Press
seekingalpha · 05/01 01:22
CareDx Reports First Quarter 2020 Results
GlobeNewswire · 04/30 21:05
CareDx Q1 EPS $0.00 Misses $0.03 Est., Sales $38.400M Beat $37.990M Estimate
CareDx (NASDAQ:CDNA) reported quarterly sales of $38.400 million which beat the analyst consensus estimate of $37.990 million by 1.08 percent. This is a 47.79 percent increase over sales of $25.982 million the same
Benzinga · 04/30 20:14
CareDx Q1 2020 Earnings Preview
CareDx (NASDAQ:CDNA) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close. The consensus EPS Estimate is $0.03 (-40.0%
seekingalpha · 04/30 02:35
Notable earnings after Thursday's close
Seeking Alpha - Article · 04/29 21:35
CareDx Engages European Lab Community in Virtual Meetings
SOUTH SAN FRANCISCO, Calif., April 27, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
GlobeNewswire · 04/27 11:00
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market.
Benzinga · 04/26 20:37